Dr Lary A Robinson, MD

Dr. Robinson, a native of Kansas, received his undergraduate B.A. degree in anthropology at the University of Kansas and his medical degree from the Washington University School of Medicine in St. Louis, Missouri. He completed his internship and residency in general and cardiothoracic surgery at the Duke University Medical Center. Additionally, he completed a fellowship in cardiac research and clinical cardiac surgery at the St. Thomas' Hospital in London. He also served as a Flight Surgeon at the rank of Major, USAF in Thailand during the Vietnam War. A Diplomat of the American Board of Surgery, the American Board of Thoracic Surgery as well as certified in Surgical Critical Care, Dr. Robinson began his practice at the University of Nebraska Medical Center where he was an Associate Professor of Surgery and Pharmacology and the Clinical Director of the Clinical Perfusion Science Education Program. Dr. Robinson then came to the University of South Florida College of Medicine in Tampa …in 1994 where he is currently a Professor of Surgery (Thoracic) and Interdisciplinary Oncology. He practices thoracic surgical oncology at the Moffitt Cancer Center as a Senior Member with Tenure of the Moffitt Medical Group. He is Director, Lung Cancer Early Detection (LEAD) Center at Moffitt which includes the Lung Cancer Screening Program, Lung Nodule Clinic and Lung Surveillance Clinic.Dr. Robinson is the author or co-author of over 180 medical publications. He is Principal Investigator on research protocols involving risk factors for developing lung cancer in never-smoking women, the use of biomarkers for early lung cancer diagnosis, nutritional prehabilitation to improve immunotherapy response in advanced lung cancer, and a clinical study evaluating the influence of nutrition and the gut microbiome on the effectiveness of immunotherapy. Clinically, he is a member of the multidisciplinary thoracic oncology group involved in the evaluation and treatment of all stages of lung cancer, thymoma, and other thoracic cancers which includes aggressive, combined modality therapy including numerous clinical trials.